

Paolo Martelletti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5533259/publications.pdf>

Version: 2024-02-01

303

papers

8,997

citations

44069

48

h-index

69250

77

g-index

316

all docs

316

docs citations

316

times ranked

6093

citing authors

#	ARTICLE	IF	CITATIONS
1	European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. Journal of Headache and Pain, 2019, 20, 6.	6.0	260
2	Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). Journal of Headache and Pain, 2012, 13, 361-378.	6.0	248
3	Aids to management of headache disorders in primary care (2nd edition). Journal of Headache and Pain, 2019, 20, 57.	6.0	195
4	Diagnosis and management of migraine in ten steps. Nature Reviews Neurology, 2021, 17, 501-514.	10.1	194
5	Air Pollution and the Novel Covid-19 Disease: a Putative Disease Risk Factor. SN Comprehensive Clinical Medicine, 2020, 2, 383-387.	0.6	189
6	Noninvasive vagus nerve stimulation as acute therapy for migraine. Neurology, 2018, 91, e364-e373.	1.1	186
7	Headache disorders are third cause of disability worldwide. Journal of Headache and Pain, 2015, 16, 58.	6.0	179
8	Gut-brain Axis and migraine headache: a comprehensive review. Journal of Headache and Pain, 2020, 21, 15.	6.0	179
9	Neuromodulation of chronic headaches: position statement from the European Headache Federation. Journal of Headache and Pain, 2013, 14, 86.	6.0	178
10	European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. Journal of Headache and Pain, 2022, 23, .	6.0	143
11	Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Journal of Headache and Pain, 2017, 18, 108.	6.0	130
12	My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. Journal of Headache and Pain, 2018, 19, 115.	6.0	130
13	Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. Journal of Headache and Pain, 2009, 10, 283-290.	6.0	129
14	European headache federation consensus on the definition of resistant and refractory migraine. Journal of Headache and Pain, 2020, 21, 76.	6.0	126
15	A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. Journal of Headache and Pain, 2015, 17, 1.	6.0	120
16	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. Journal of Headache and Pain, 2019, 20, 92.	6.0	116
17	Gepants for the treatment of migraine. Expert Opinion on Investigational Drugs, 2019, 28, 555-567.	4.1	106
18	Underdiagnosis and Undertreatment of Migraine in Italy: A Survey of Patients Attending for The First Time 10 Headache Centres. Cephalalgia, 2009, 29, 1285-1293.	3.9	103

#	ARTICLE	IF	CITATIONS
19	Migraine and sleep disorders: a systematic review. Journal of Headache and Pain, 2020, 21, 126.	6.0	99
20	European headache federation consensus on technical investigation for primary headache disorders. Journal of Headache and Pain, 2015, 17, 5.	6.0	97
21	Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. Journal of Headache and Pain, 2018, 19, 91.	6.0	97
22	Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation. Journal of Headache and Pain, 2014, 15, 79.	6.0	95
23	Chronic migraine plus medication overuse headache: two entities or not?. Journal of Headache and Pain, 2011, 12, 593-601.	6.0	87
24	Refractory chronic migraine: a Consensus Statement on clinical definition from the European Headache Federation. Journal of Headache and Pain, 2014, 15, 47.	6.0	86
25	Developing a core outcome domain set to assessing effectiveness of interdisciplinary multimodal pain therapy: the VAPAIN consensus statement on core outcome domains. Pain, 2018, 159, 673-683.	4.2	86
26	Association of diet and headache. Journal of Headache and Pain, 2019, 20, 106.	6.0	84
27	Chronic migraine: comorbidities, risk factors, and rehabilitation. Internal and Emergency Medicine, 2010, 5, 13-19.	2.0	82
28	Psychiatric comorbidity and suicide risk in patients with chronic migraine. Neuropsychiatric Disease and Treatment, 2010, 6, 81.	2.2	81
29	â€œIctal epileptic headacheâ€™: Recent concepts for new classifications criteria. Cephalalgia, 2012, 32, 723-724.	3.9	79
30	Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection. American Journal of Infection Control, 2021, 49, 640-642.	2.3	78
31	Comorbidities of primary headache disorders: a literature review with meta-analysis. Journal of Headache and Pain, 2021, 22, 71.	6.0	78
32	A six year retrospective review of occipital nerve stimulation practice - controversies and challenges of an emerging technique for treating refractory headache syndromes. Journal of Headache and Pain, 2013, 14, 67.	6.0	77
33	CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?. Journal of Headache and Pain, 2019, 20, 27.	6.0	77
34	The Global Campaign, World Health Organization and Lifting The Burden: collaboration in action. Journal of Headache and Pain, 2011, 12, 273-274.	6.0	75
35	Lifting The Burden: the first 7Â½years. Journal of Headache and Pain, 2010, 11, 451-455.	6.0	70
36	Impact of migraine on fibromyalgia symptoms. Journal of Headache and Pain, 2016, 17, 28.	6.0	69

#	ARTICLE	IF	CITATIONS
37	Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. <i>Journal of Pain Research</i> , 2018, Volume 11, 515-526.	2.0	67
38	Reduction of Multidrug-Resistant (MDR) Bacterial Infections during the COVID-19 Pandemic: A Retrospective Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1003.	2.6	66
39	Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). <i>Journal of Headache and Pain</i> , 2018, 19, 76.	6.0	64
40	CGRP receptor antagonists: an expanding drug class for acute migraine?. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 807-818.	4.1	63
41	Emerging treatment for chronic migraine and refractory chronic migraine. <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 393-406.	2.4	63
42	OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. <i>SpringerPlus</i> , 2015, 4, 826.	1.2	62
43	An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. <i>Journal of Headache and Pain</i> , 2019, 20, 26.	6.0	61
44	Altered kynurenine pathway metabolites in serum of chronic migraine patients. <i>Journal of Headache and Pain</i> , 2016, 17, 47.	6.0	57
45	Tumor Necrosis Factor Gene Polymorphism in Migraine. <i>Headache</i> , 2002, 42, 341-345.	3.9	55
46	Improving care through health economics analyses: cost of illness and headache. <i>Journal of Headache and Pain</i> , 2008, 9, 199-206.	6.0	53
47	New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters?. <i>Journal of Headache and Pain</i> , 2013, 14, 9.	6.0	53
48	Ictal epileptic headache: an old story with courses and appeals. <i>Journal of Headache and Pain</i> , 2012, 13, 607-613.	6.0	52
49	Cervical 10ÂkHz spinal cord stimulation in the management of chronic, medically refractory migraine: A prospective, openâ€label, exploratory study. <i>European Journal of Pain</i> , 2016, 20, 70-78.	2.8	50
50	New IgM seroconversion and positive RTâ€PCR test after exposure to the virus in recovered COVIDâ€19 patient. <i>Journal of Medical Virology</i> , 2021, 93, 97-98.	5.0	50
51	Structural and Functional Brain Changes in Migraine. <i>Pain and Therapy</i> , 2021, 10, 211-223.	3.2	48
52	Inhibition of intercellular adhesion molecule-1 (ICAM-1), soluble ICAM-1 and interleukin-4 by nitric oxide expression in migraine patients. <i>Journal of Molecular Medicine</i> , 1997, 75, 448-453.	3.9	47
53	Cervicogenic Headache. <i>CNS Drugs</i> , 2004, 18, 793-805.	5.9	47
54	A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. <i>Journal of Headache and Pain</i> , 2011, 12, 361-368.	6.0	47

#	ARTICLE	IF	CITATIONS
55	Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. <i>Journal of Headache and Pain</i> , 2019, 20, 120.	6.0	46
56	Optimising migraine treatment: from drug-drug interactions to personalized medicine. <i>Journal of Headache and Pain</i> , 2019, 20, 56.	6.0	45
57	Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 627-641.	2.8	45
58	Emerging drugs for migraine treatment: an update. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 301-318.	2.4	44
59	Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. <i>Journal of Headache and Pain</i> , 2022, 23, 41.	6.0	43
60	Salivary cortisol, dehydroepiandrosteronesulphate (DHEAâ€‘S) and testosterone in women with chronic migraine. <i>Journal of Headache and Pain</i> , 2006, 7, 90-94.	6.0	42
61	Genetics of migraine and pharmacogenomics: some considerations. <i>Journal of Headache and Pain</i> , 2007, 8, 334-339.	6.0	42
62	Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3â€‘Years of Therapy. <i>Frontiers in Neurology</i> , 2017, 8, 586.	2.4	42
63	Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. <i>Internal and Emergency Medicine</i> , 2020, 15, 1467-1476.	2.0	42
64	Altered serum levels of kynurenine metabolites in patients affected by cluster headache. <i>Journal of Headache and Pain</i> , 2016, 17, 27.	6.0	41
65	Long-COVID Headache. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1704-1706.	0.6	40
66	Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. <i>Journal of Pain Research</i> , 2017, Volume 10, 2751-2760.	2.0	39
67	Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. <i>Journal of Headache and Pain</i> , 2021, 22, 39.	6.0	39
68	Anti-CGRP monoclonal antibodies in migraine: current perspectives. <i>Internal and Emergency Medicine</i> , 2016, 11, 1045-1057.	2.0	38
69	The Global Burden of Disease survey 2010, Lifting The Burden and thinking outside-the-box on headache disorders. <i>Journal of Headache and Pain</i> , 2013, 14, 13.	6.0	37
70	COVID-19: is it just a lung disease? A case-based review. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1401-1406.	0.6	37
71	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , 2021, 16, 1005-1015.	2.0	37
72	Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence. <i>Journal of Headache and Pain</i> , 2020, 21, 55.	6.0	37

#	ARTICLE	IF	CITATIONS
73	Lasmiditan for the treatment of migraine. Expert Opinion on Investigational Drugs, 2017, 26, 227-234.	4.1	36
74	Medication overuse and drug addiction: a narrative review from addiction perspective. Journal of Headache and Pain, 2021, 22, 32.	6.0	36
75	Global Burden of Headache Disorders in Children and Adolescents 2007-2017. International Journal of Environmental Research and Public Health, 2021, 18, 250.	2.6	36
76	Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. Journal of Headache and Pain, 2006, 7, 407-412.	6.0	34
77	Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. Journal of Headache and Pain, 2010, 11, 431-435.	6.0	34
78	Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 101.	6.0	34
79	Emerging drugs for migraine treatment. Expert Opinion on Emerging Drugs, 2015, 20, 137-147.	2.4	33
80	The therapeutic armamentarium in migraine is quite elderly. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 175-177.	3.3	32
81	Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. Journal of Headache and Pain, 2012, 13, 401-406.	6.0	31
82	Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. Journal of Headache and Pain, 2010, 11, 151-156.	6.0	30
83	The omics in migraine. Journal of Headache and Pain, 2013, 14, 55.	6.0	30
84	Correlation between Migraine Severity and Cholesterol Levels. Pain Practice, 2015, 15, 662-670.	1.9	30
85	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review. SN Comprehensive Clinical Medicine, 2020, 2, 694-699.	0.6	30
86	Time to act on headache disorders. Journal of Headache and Pain, 2011, 12, 501-503.	6.0	29
87	Improving quality in population surveys of headache prevalence, burden and cost: key methodological considerations. Journal of Headache and Pain, 2013, 14, 87.	6.0	29
88	Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 399-406.	3.3	29
89	Acute headache management in emergency department. A narrative review. Internal and Emergency Medicine, 2020, 15, 109-117.	2.0	29
90	The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE). Journal of Headache and Pain, 2005, 6, 261-263.	6.0	28

#	ARTICLE	IF	CITATIONS
91	Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache. <i>Journal of Headache and Pain</i> , 2008, 9, 349-357.	6.0	28
92	Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. <i>Therapeutic Advances in Neurological Disorders</i> , 2016, 9, 414-423.	3.5	28
93	Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, mu. <i>International Journal of Clinical Practice</i> , 2007, 61, 1256-1269.	1.7	27
94	Prevalence and burden of primary headache in Akaki textile mill workers, Ethiopia. <i>Journal of Headache and Pain</i> , 2008, 9, 119-128.	6.0	27
95	Future drugs for migraine. <i>Internal and Emergency Medicine</i> , 2009, 4, 367-373.	2.0	27
96	Sumatriptan succinate: pharmacokinetics of different formulations in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2369-2380.	1.8	27
97	Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. <i>Journal of Headache and Pain</i> , 2017, 18, 66.	6.0	27
98	Non-Pharmacological Approaches to Headaches: Non-Invasive Neuromodulation, Nutraceuticals, and Behavioral Approaches. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1503.	2.6	27
99	Chromosome 6p-encoded HLA-DR2 determinant discriminates migraine without aura from migraine with aura. <i>Human Immunology</i> , 1999, 60, 69-74.	2.4	26
100	Persistent Post-Traumatic Headache and Migraine: Pre-Clinical Comparisons. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 2585.	2.6	26
101	Modulation of nitric oxide synthase by nitric oxide donor compounds in migraine. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 135-139.	1.0	25
102	Use of Nonsteroidal Anti-Inflammatory Drugs for Symptomatic Treatment of Episodic Headache. <i>Pain Practice</i> , 2017, 17, 392-401.	1.9	25
103	Ubrogepant for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 755-759.	1.8	25
104	Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 313-317.	2.8	25
105	"Capsaicin-Sensitive" Sensory Neurons in Cluster Headache: Pathophysiological Aspects and Therapeutic Indication. <i>Headache</i> , 1994, 34, 132-137.	3.9	24
106	Headache service quality: evaluation of quality indicators in 14 specialist-care centres. <i>Journal of Headache and Pain</i> , 2016, 17, 111.	6.0	24
107	Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 167-176.	2.8	24
108	Shaping the future of migraine targeting Calcitonin-Gen-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). <i>Journal of Headache and Pain</i> , 2019, 20, 60.	6.0	24

#	ARTICLE	IF	CITATIONS
109	Persistent post-traumatic headache: a migrainous loop or not? The preclinical evidence. <i>Journal of Headache and Pain</i> , 2020, 21, 90.	6.0	24
110	Chronic migraine: current concepts and ongoing treatments. <i>European Review for Medical and Pharmacological Sciences</i> , 2011, 15, 1401-20.	0.7	24
111	Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important. <i>Internal and Emergency Medicine</i> , 2015, 10, 413-421.	2.0	23
112	Putative Neuroimmunological Mechanisms in Cluster Headache. An Integrated Hypothesis. <i>Headache</i> , 1996, 36, 312-315.	3.9	22
113	The definitive position of headache among the major public health challenges. An end to the slippery slope of disregard. <i>Journal of Headache and Pain</i> , 2007, 8, 149-151.	6.0	22
114	Chronic migraine treatment: from OnabotulinumtoxinA onwards. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 1217-1227.	2.8	22
115	The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities. <i>BioDrugs</i> , 2017, 31, 483-485.	4.6	22
116	Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 769-776.	2.8	22
117	Extremely Severe Case of COVID-19 Pneumonia Recovered Despite Bad Prognostic Indicators: a Didactic Report. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 1204-1207.	0.6	22
118	Rapid referral for headache management from emergency department to headache centre: four years data. <i>Journal of Headache and Pain</i> , 2020, 21, 25.	6.0	22
119	Hyperbaric oxygen in chronic cluster headaches: influence on serotonergic pathways. <i>Undersea and Hyperbaric Medicine</i> , 1997, 24, 117-22.	0.3	22
120	Coinfection of Tuberculosis Pneumonia and COVID-19 in a Patient Vaccinated with Bacille Calmette-Guérin (BCG): Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2419-2422.	0.6	21
121	Aspirin and tension-type headache. <i>Journal of Headache and Pain</i> , 2007, 8, 49-55.	6.0	20
122	Sodium channel antagonists for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1697-1706.	1.8	20
123	Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. <i>Journal of Headache and Pain</i> , 2017, 18, 93.	6.0	20
124	The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine. <i>Journal of Headache and Pain</i> , 2018, 19, 2.	6.0	20
125	Recurrent COVID-19 pneumonia in the course of chemotherapy: Consequence of a weakened immune system?. <i>Journal of Medical Virology</i> , 2021, 93, 1882-1884.	5.0	20
126	CGRP Receptor Antagonists and 5-HT _{1F} Receptor Agonist in the Treatment of Migraine. <i>Journal of Clinical Medicine</i> , 2021, 10, 1429.	2.4	20

#	ARTICLE	IF	CITATIONS
127	Access to COVID-19 Vaccination during the Pandemic in the Informal Settlements of Rome. International Journal of Environmental Research and Public Health, 2022, 19, 719.	2.6	20
128	Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Expert Review of Neurotherapeutics, 2009, 9, 1267-1269.	2.8	19
129	Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 39-47.	3.3	19
130	Greater occipital nerve as target for refractory chronic headaches: from corticosteroid block to invasive neurostimulation and back. Expert Review of Neurotherapeutics, 2016, 16, 865-866.	2.8	19
131	Advances in orally administered pharmacotherapy for the treatment of migraine. Expert Opinion on Pharmacotherapy, 2019, 20, 209-218.	1.8	19
132	Position Paper on Post-Traumatic Headache: The Relationship Between Head Trauma, Stress Disorder, and Migraine. Pain and Therapy, 2021, 10, 1-13.	3.2	19
133	Deprescribing in migraine. Expert Opinion on Drug Safety, 2021, 20, 1-3.	2.4	19
134	Proinflammatory pathways in cervicogenic headache. Clinical and Experimental Rheumatology, 2000, 18, S33-8.	0.8	19
135	The validation of the Italian Perceived Disability Scale (IPDS) in chronic daily headache sufferers. Journal of Headache and Pain, 2009, 10, 21-26.	6.0	18
136	Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. Journal of Headache and Pain, 2018, 19, 98.	6.0	18
137	Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. Journal of Headache and Pain, 2018, 19, 68.	6.0	18
138	Profiling lasmiditan as a treatment option for migraine. Expert Opinion on Pharmacotherapy, 2020, 21, 147-153.	1.8	18
139	Acute sleep deprivation enhances susceptibility to the migraine substrate cortical spreading depolarization. Journal of Headache and Pain, 2020, 21, 86.	6.0	18
140	Mapping Assessments Instruments for Headache Disorders against the ICF Biopsychosocial Model of Health and Disability. International Journal of Environmental Research and Public Health, 2021, 18, 246.	2.6	18
141	Patient outcome in migraine prophylaxis: the role of psychopharmacological agents. Patient Related Outcome Measures, 2010, 1, 107.	1.2	17
142	A Critical Evaluation on MOH Current Treatments. Current Treatment Options in Neurology, 2017, 19, 32.	1.8	17
143	Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Preventive treatment of migraine. Drugs of the Future, 2020, 45, 285.	0.1	17
144	How Does COVID-19 Pandemic Impact on Incidence of Clostridioides difficile Infection and Exacerbation of Its Gastrointestinal Symptoms?. Frontiers in Medicine, 2021, 8, 775063.	2.6	17

#	ARTICLE	IF	CITATIONS
145	Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class. <i>Expert Review of Neurotherapeutics</i> , 2008, 8, 1347-1354.	2.8	16
146	Pharmacokinetic evaluation of frovatriptan. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1449-1458.	3.3	16
147	Treatment of Perimenstrual Migraine with Triptans: an Update. <i>Current Pain and Headache Reports</i> , 2012, 16, 445-451.	2.9	16
148	Overattachment and perceived disability in chronic migraineurs. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 954-958.	1.4	16
149	Combination therapy in migraine: asset or issue?. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 995-996.	2.8	16
150	Headache as a Prognostic Factor for COVID-19. Time to Re-evaluate. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 2509-2510.	0.6	16
151	Direct and indirect costs of cluster headache: a prospective analysis in a tertiary level headache centre. <i>Journal of Headache and Pain</i> , 2020, 21, 44.	6.0	16
152	The Relation between Persistent Post-Traumatic Headache and PTSD: Similarities and Possible Differences. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4024.	2.6	16
153	Progressive Deactivation of 5HT Receptors on Mononuclear Cells during Migraine Crisis. <i>Cephalalgia</i> , 1989, 9, 93-94.	3.9	15
154	Evidence for an Immune-Mediated Mechanism in Food-Induced Migraine from a Study on Activated T-Cells, IgG 4 Subclass, Anti-IgG Antibodies and Circulating Immune Complexes. <i>Headache</i> , 1989, 29, 664-670.	3.9	15
155	Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse?. <i>Internal and Emergency Medicine</i> , 2011, 6, 23-28.	2.0	15
156	Psychometric properties of the stagnation scale in medication overuse headache patients. <i>Journal of Headache and Pain</i> , 2015, 16, 1052.	6.0	15
157	Cluster headache treatment “ RCTs versus real-world evidence. <i>Nature Reviews Neurology</i> , 2016, 12, 557-558.	10.1	15
158	Coronavirus disease 2019 in patients with cardiovascular disease: clinical features and implications on cardiac biomarkers assessment. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 832-839.	1.5	15
159	Novel synthetic treatment options for migraine. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 907-922.	1.8	15
160	Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study. <i>Pain and Therapy</i> , 2021, 10, 1691-1708.	3.2	15
161	Proinflammatory cytokines in cervicogenic headache. <i>Functional Neurology</i> , 1999, 14, 159-62.	1.3	15
162	Acute migraine in the Emergency Department: extending European principles of management. <i>Internal and Emergency Medicine</i> , 2008, 3, 17-24.	2.0	14

#	ARTICLE	IF	CITATIONS
163	Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 1043-1050.	3.3	14
164	What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. Expert Review of Neurotherapeutics, 2020, 20, 1275-1286.	2.8	14
165	Epidural corticosteroid blockade in cervicogenic headache. European Review for Medical and Pharmacological Sciences, 1998, 2, 31-6.	0.7	14
166	The Global Campaign turns 18: a brief review of its activities and achievements. Journal of Headache and Pain, 2022, 23, 49.	6.0	14
167	White matter hyperintensities and self-reported depression in a sample of patients with chronic headache. Journal of Headache and Pain, 2012, 13, 661-667.	6.0	13
168	Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity. Expert Opinion on Pharmacotherapy, 2014, 15, 303-305.	1.8	13
169	Erenumab is effective in reducing migraine frequency and improving physical functioning. BMJ Evidence-Based Medicine, 2019, 24, 76-76.	3.5	13
170	Fremanezumab for the preventive treatment of migraine in adults. Expert Review of Clinical Pharmacology, 2019, 12, 741-748.	3.1	13
171	How do you choose the appropriate migraine pharmacotherapy for an elderly person?. Expert Opinion on Pharmacotherapy, 2019, 20, 1-3.	1.8	13
172	Recent advancements in tension-type headache: a narrative review. Expert Review of Neurotherapeutics, 2021, 21, 793-803.	2.8	13
173	Neurological and Mental Health Symptoms Associated with Post-COVID-19 Disability in a Sample of Patients Discharged from a COVID-19 Ward: A Secondary Analysis. International Journal of Environmental Research and Public Health, 2022, 19, 4242.	2.6	13
174	Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics, 2014, 15, 1539-1550.	1.3	12
175	Cluster headache management and beyond. Expert Opinion on Pharmacotherapy, 2015, 16, 1411-1415.	1.8	12
176	Update on Medication-Overuse Headache and Its Treatment. Current Treatment Options in Neurology, 2015, 17, 368.	1.8	12
177	Pharmacogenetic considerations for migraine therapies. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1-7.	3.3	12
178	Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine. CNS Drugs, 2018, 32, 559-565.	5.9	12
179	Migraine and cluster headache show impaired neurosteroids patterns. Journal of Headache and Pain, 2019, 20, 61.	6.0	12
180	Evaluating and managing severe headache in the emergency department. Expert Review of Neurotherapeutics, 2021, 21, 277-285.	2.8	12

#	ARTICLE	IF	CITATIONS
181	Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. Pain and Therapy, 2021, 10, 637-650.	3.2	12
182	Fremanezumab for the prevention of chronic and episodic migraine. Drugs of Today, 2019, 55, 265.	1.1	12
183	Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1381-1395.	3.3	11
184	Cluster headache: a quasi-rare disorder needing a reappraisal. Journal of Headache and Pain, 2015, 16, 59.	6.0	11
185	Lack of association between oxidative stress-related gene polymorphisms and chronic migraine in an Italian population. Expert Review of Neurotherapeutics, 2015, 15, 215-225.	2.8	11
186	Using INTERCheck® to Evaluate the Incidence of Adverse Events and Drug-Drug Interactions in Out- and Inpatients Exposed to Polypharmacy. Drugs - Real World Outcomes, 2020, 7, 243-249.	1.6	11
187	Aids for management of common headache disorders in primary care. Journal of Headache and Pain, 2007, 8 Suppl 1, S2.	6.0	11
188	Positioning the new drugs for migraine. Expert Opinion on Drug Metabolism and Toxicology, 2022, , 1-3.	3.3	11
189	Job Satisfaction Mediates the Association between Perceived Disability and Work Productivity in Migraine Headache Patients. International Journal of Environmental Research and Public Health, 2019, 16, 3341.	2.6	10
190	Healthcare resource use and indirect costs associated with migraine in Italy: results from the My Migraine Voice survey. Journal of Medical Economics, 2021, 24, 717-726.	2.1	10
191	Rimegepant for the treatment of migraine. Drugs of Today, 2020, 56, 769.	1.1	10
192	Nitric oxide: emerging implications for headache mechanics. Journal of Headache and Pain, 2001, 2, 67-72.	6.0	9
193	Inflammatory mechanisms in cervicogenic headache: An integrative view. Current Pain and Headache Reports, 2002, 6, 315-319.	2.9	9
194	Migraine disability complicated by medication overuse. European Journal of Neurology, 2018, 25, 1193-1194.	3.3	9
195	The clinical and public health implications and risks of widening the definition of chronic migraine. Cephalalgia, 2020, 40, 407-410.	3.9	9
196	Reduction in expenditures on analgesics during one year of treatment of chronic tension headache with BoNT-A. Journal of Headache and Pain, 2003, 4, 88-91.	6.0	8
197	Role of NSAIDs in acute treatment of headache. Drug Development Research, 2007, 68, 276-281.	2.9	8
198	Efficacy and tolerability of almotriptan in menstrual migraine: a comment. Expert Opinion on Pharmacotherapy, 2011, 12, 2279-2281.	1.8	8

#	ARTICLE	IF	CITATIONS
199	Pharmacokinetic evaluation of almotriptan for the treatment of migraines. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 637-644.	3.3	8
200	Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. Pain and Therapy, 2021, 10, 1605-1618.	3.2	8
201	Etiology of “Sinus Headache” Moving the Focus from Rhinology to Neurology. A Systematic Review. Brain Sciences, 2021, 11, 79.	2.3	8
202	Tele-healthcare in migraine medicine: from diagnosis to monitoring treatment outcomes. Expert Review of Neurotherapeutics, 2022, 22, 237-243.	2.8	8
203	In vitro interactions of serotonin (5-HT) with mononuclear cells from migraine patients: alterations related to the phase of the attack. Journal of Neuroimmunology, 1988, 18, 17-24.	2.3	7
204	Headache and mood disorders. Journal of Headache and Pain, 2005, 6, 250-253.	6.0	7
205	Dispute settlement understanding on the use of BOTOX® in chronic migraine. Journal of Headache and Pain, 2011, 12, 1-2.	6.0	7
206	Treatment of menstrual migraine: utility of control of related mood disturbances. Expert Review of Neurotherapeutics, 2014, 14, 493-502.	2.8	7
207	Refractory Headache: One Term does Not cover All “ A Statement of the European Headache Federation. Journal of Headache and Pain, 2014, 15, 50.	6.0	7
208	The therapeutic potential of novel anti-migraine acute therapies. Expert Opinion on Investigational Drugs, 2015, 24, 141-144.	4.1	7
209	Depression and insomnia are independently associated with satisfaction and enjoyment of life in medication-overuse headache patients. International Journal of Psychiatry in Medicine, 2016, 51, 442-455.	1.8	7
210	Illness Perception and Job Satisfaction in Patients Suffering from Migraine Headaches: Trait Anxiety and Depressive Symptoms as Potential Mediators. Headache, 2019, 59, 46-55.	3.9	7
211	The future of pharmacogenetics in the treatment of migraine. Pharmacogenomics, 2019, 20, 1159-1173.	1.3	7
212	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. Journal of Headache and Pain, 2019, 20, 15.	6.0	7
213	Eptinezumab for the treatment of migraine. Expert Opinion on Biological Therapy, 2021, 21, 999-1011.	3.1	7
214	Unmet needs for migraine. Current Medical Research and Opinion, 2021, 37, 1957-1959.	1.9	7
215	Zavegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraine. Drugs of the Future, 2021, 46, 281.	0.1	7
216	Rimegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraine. Drugs of the Future, 2019, 44, 635.	0.1	7

#	ARTICLE	IF	CITATIONS
217	Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine. <i>BioDrugs</i> , 2022, 36, 337-339.	4.6	7
218	Headache Medicine: Academic Teaching in Europe. The <i>Sapienza</i> University Master's Degree. <i>Headache</i> , 2007, 47, 1224-1225.	3.9	6
219	Deciphering the task of N-acetyl aspartate in migraine. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1057-1059.	2.8	6
220	Acute treatment of migraine: <i>quo vadis?</i> . <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1035-1037.	1.8	6
221	Hormonal therapies in migraine management: current perspectives on patient selection and risk management. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1347-1355.	2.8	6
222	Failure of long-term results of epidural steroid injection in cervicogenic headache. <i>European Review for Medical and Pharmacological Sciences</i> , 1998, 2, 10.	0.7	6
223	The global impact of migraine. <i>Journal of Headache and Pain</i> , 2003, 4, s1-s2.	6.0	5
224	Analgesic therapy for headache: consumption, appropriateness and costs. <i>Journal of Headache and Pain</i> , 2003, 4, s84-s87.	6.0	5
225	A one-year retrospective economic evaluation of botulinum toxin type A treatment of chronic tension headache. <i>Journal of Headache and Pain</i> , 2004, 5, 188-191.	6.0	5
226	Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1011-1020.	3.3	5
227	Pituitary adenylate-cyclase-activating polypeptide (PACAP): another novel target for treatment of primary headaches?. <i>Journal of Headache and Pain</i> , 2018, 19, 33.	6.0	5
228	Multiple Chemical Sensitivity Syndrome: A Principal Component Analysis of Symptoms. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 6551.	2.6	5
229	An unexpected and suspended time. <i>Journal of Headache and Pain</i> , 2020, 21, 36.	6.0	5
230	Academic specialist education in headache medicine. Next move for the headache community. <i>Journal of Headache and Pain</i> , 2005, 6, 103-104.	6.0	4
231	O068. A 2 years prospective evaluation study on onabotulinumtoxinA 195 U in chronic migraine. <i>Journal of Headache and Pain</i> , 2015, 16, A177.	6.0	4
232	Tackling the perils of unawareness: the cluster headache case. <i>Journal of Headache and Pain</i> , 2017, 18, 49.	6.0	4
233	Approaching the appropriate pharmacotherapy of menstrual migraine. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1-2.	2.8	4
234	Polyamines serum levels in episodic and chronic migraine. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 249-254.	2.8	4

#	ARTICLE	IF	CITATIONS
235	Cluster Headache is Still Lurking in the Shadows. Pain and Therapy, 2021, 10, 777-781.	3.2	4
236	Upregulated expression of peripheral serotonergic receptors in migraine and cluster headache by sumatriptan. International Journal of Clinical Pharmacology Research, 1994, 14, 165-75.	0.4	4
237	Epidural steroid-based technique for cervicogenic headache diagnosis. Functional Neurology, 1998, 13, 84-7.	1.3	4
238	Migraine Outcome Should Not Be Used to Determine Diagnosis, Severity, and Therapy: Moving Towards a Multiparametric Definition of Chronicity. Pain and Therapy, 2022, 11, 331-339.	3.2	4
239	Narrative-based medicine in headache disorders. Journal of Headache and Pain, 2022, 23, .	6.0	4
240	Recently approved and emerging drug options for migraine prophylaxis. Expert Opinion on Pharmacotherapy, 2022, 23, 1325-1335.	1.8	4
241	Raised Titers Of Antibodies To Herpes And Epstein-Barr Viruses In Cluster Headache Detected By Emjnofluorescence. Cephalalgia, 1987, 7, 351-352.	3.9	3
242	Cytotoxic T lymphocyte antigen 4 polymorphism 49 (A>G) and migraine. Journal of Headache and Pain, 2005, 6, 188-190.	6.0	3
243	Neuroendocrine Derangement in Chronic Migraine. Headache, 2006, 46, 1309-1310.	3.9	3
244	Headache and emergency medicine: sharing a language for a common project. Internal and Emergency Medicine, 2008, 3, 1-2.	2.0	3
245	Framing education on headache disorders into the Global Burden of Disease Study 2010. The European Headache Federation stands ready. Journal of Headache and Pain, 2013, 14, 41.	6.0	3
246	An unaddicted impact factor. Journal of Headache and Pain, 2013, 14, 58.	6.0	3
247	P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine. Journal of Headache and Pain, 2015, 16, A137.	6.0	3
248	Lifting The Burden: The Global Campaign Against Headache. , 2011, , 737-744.		3
249	The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer's disease. F1000Research, 2020, 9, 1470.	1.6	3
250	Insights into headache 2022. Expert Review of Neurotherapeutics, 2022, , 1-3.	2.8	3
251	Chronic daily headache and medication overuse headache: clinical read-outs and rehabilitation procedures. Clinica Terapeutica, 2007, 158, 343-7.	0.1	3
252	The evaluation of the intracavitary effusions by a bedside ultrasound examination. Clinical Hemorheology and Microcirculation, 2022, 81, 233-240.	1.7	3

#	ARTICLE	IF	CITATIONS
253	Health status after detoxification in medication overuse headache. Journal of Headache and Pain, 2004, 5, 215-216.	6.0	2
254	The road ahead for chronic headache patients. Journal of Headache and Pain, 2006, 7, 317-319.	6.0	2
255	A tier-upon-tier march towards the impact factor. Journal of Headache and Pain, 2008, 9, 197-198.	6.0	2
256	New policies to consolidate the journal's hold on its latest position. Journal of Headache and Pain, 2009, 10, 1-2.	6.0	2
257	While climbing the hill, you think it's possible. Journal of Headache and Pain, 2009, 10, 309-310.	6.0	2
258	The Journal of Headache and Pain keeps gaining consensus. Journal of Headache and Pain, 2010, 11, 287-288.	6.0	2
259	A tasty cultural event. Journal of Headache and Pain, 2012, 13, 435-436.	6.0	2
260	P067. Multimodal therapy in the management of MOH: a 3-year experience. Journal of Headache and Pain, 2015, 16, A135.	6.0	2
261	P064. 12 years of Master Degree in Headache Medicine at Sapienza University of Rome. Journal of Headache and Pain, 2015, 16, A187.	6.0	2
262	O065. Drug-resistant chronic cluster headache successfully treated with supraorbital plus occipital nerve stimulation. A rare case report. Journal of Headache and Pain, 2015, 16, A97.	6.0	2
263	Questioning on consistency of a Stagnation Scale in Medication Overuse Headache: one more added to a plea of emperor's clothes?. Journal of Headache and Pain, 2015, 16, 13.	6.0	2
264	Changing the Approach to Anticoagulant Therapy in Older Patients with Multimorbidity Using a Precision Medicine Approach. International Journal of Environmental Research and Public Health, 2018, 15, 1634.	2.6	2
265	New Model for Non-Invasive Echocardiographic Assessment of Pulmonary-Capillary Wedge Pressure in Patients With Aortic and Mitral Regurgitation. SN Comprehensive Clinical Medicine, 2020, 2, 914-918.	0.6	2
266	The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer's disease. F1000Research, 2020, 9, 1470.	1.6	2
267	Immune Response Time-Course after Challenge Test in Food-Induced Migraine. Cephalalgia, 1989, 9, 164-165.	3.9	1
268	Il-2 Induces Proliferation in Peripheral Blood Mononuclear Cells from Cluster Headache Patients. Cephalalgia, 1991, 11, 270-271.	3.9	1
269	Bioelectrical Impedance Assay (BIA) of Total Body Composition in Alcohol-Induced Migraine Patients. Preliminary Report.. Headache, 1991, 31, 41-45.	3.9	1
270	Starting Tutorials in headache medicine education. Journal of Headache and Pain, 2006, 7, 55-56.	6.0	1

#	ARTICLE	IF	CITATIONS
271	Thoughts on the past year of Journal of Headache and Pain. Journal of Headache and Pain, 2008, 9, 1-2.	6.0	1
272	Chronicling the June conundrum. Journal of Headache and Pain, 2011, 12, 397-398.	6.0	1
273	Framing comorbidities and co-occurrences in a migraine with aura patient. Internal and Emergency Medicine, 2014, 9, 603-604.	2.0	1
274	Choosing the safest acute combination therapy during prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. Journal of Headache and Pain, 2015, 16, A36.	6.0	1
275	P003. NSAIDs for symptomatic treatment of headache. Journal of Headache and Pain, 2015, 16, A162.	6.0	1
276	O066. Kynurenine pathway metabolites in cluster headache. Journal of Headache and Pain, 2015, 16, A87.	6.0	1
277	EV435Life satisfaction and enjoyment in medication-overuse headache patients: The role of depression and insomnia. European Psychiatry, 2016, 33, S395-S395.	0.2	1
278	Cognition, disability and quality of life of patients with chronic migraine. European Psychiatry, 2017, 41, s501-s501.	0.2	1
279	The changing faces of migraine. Journal of Headache and Pain, 2019, 20, 52.	6.0	1
280	Unmet Needs in Headache Management. Headache, 2019, , 13-25.	0.4	1
281	New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient. , 2021, 93, 97.		1
282	Headache disorders: Building specialist education. , 2010, , 173-178.		1
283	CHA2DS2-VASc score in patients with COVID-19 pneumonia and its relationship with biomarkers of thrombosis, inflammation and myocardial injury. Blood Coagulation and Fibrinolysis, 2021, Publish Ahead of Print, .	1.0	1
284	Dismantling the Barriers. Headache, 2019, , 185-201.	0.4	1
285	Comparison of Computerized Prescription Support Systems in COVID-19 Patients: INTERCheck and Drug-PIN. SN Comprehensive Clinical Medicine, 2021, 4, 3.	0.6	1
286	Practical Insights on the Identification and Management of Patients with Chronic Migraine. Pain and Therapy, 2022, , .	3.2	1
287	Reduced IL-2 Receptor Expression on Peripheral Blood Lymphocytes from Cluster Headache Patients. Cephalalgia, 1989, 9, 162-163.	3.9	0
288	Gleaning after the European Headache Federation consensus statement on refractory chronic migraine. Journal of Headache and Pain, 2014, 15, 75.	6.0	0

#	ARTICLE	IF	CITATIONS
289	Journal Citation Reports® 2013 tells headache experts that competitive environment has changed. Journal of Headache and Pain, 2014, 15, .	6.0	0
290	Invasive neurostimulation. Journal of Headache and Pain, 2015, 16, A29.	6.0	0
291	The changing comet. Journal of Headache and Pain, 2017, 18, 65.	6.0	0
292	Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. Frontiers in Neurology, 2018, 9, .	2.4	0
293	Cytomegalovirus Reactivation in Critically Ill Patient: Cause or Consequence? A Case Report and Literature Review. SN Comprehensive Clinical Medicine, 2019, 1, 633-636.	0.6	0
294	Prophylactic Drugs. Headache, 2020, , 135-151.	0.4	0
295	Flail Mitral Valve Associated with Iliac Artery Aneurysm: Diagnostic Challenges of a Potential Syndromic Pattern. Case Report. SN Comprehensive Clinical Medicine, 2020, 2, 481-484.	0.6	0
296	Two decades, a new editorial stylistic feature. Journal of Headache and Pain, 2020, 21, 7.	6.0	0
297	“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies. Pain and Therapy, 2020, 9, 349-351.	3.2	0
298	Migraine Versus Cluster Headache and Potential Other Indications. Headache, 2021, , 167-172.	0.4	0
299	Right Heart Thrombus and Pulmonary Embolism in Patients with Life-Threatening Bleeding: Management of a Complex Condition. SN Comprehensive Clinical Medicine, 2021, 3, 793-795.	0.6	0
300	The baton changed hands. Journal of Headache and Pain, 2021, 22, 88.	6.0	0
301	Medical Interventions for Migraine That Has Become Difficult to Treat. , 2011, , 423-434.		0
302	Treatment and Prevention of Migraine. , 2011, , 255-263.		0
303	Refractory Chronic Migraine: Therapy with Combined Peripheral Neurostimulation. Headache, 2015, , 75-80.	0.4	0